ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY KHÁNG TKI: CA LÂM SÀNG THỰC TIỄN TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC THÀNH PHỐ HỒ CHÍ MINH VÀ Y VĂN

Background: We describe the characteristics, management, and clinical outcomes of patients with chronic myeloid leukemia (CML) who exhibit resistance to tyrosine kinase inhibitors (TKIs).Case presentation: We report two cases of imatinib-resistant CML, detailing their management and follow-up to the present. Information regarding diagnosis, clinical features, treatment history, and assessments before and after switching TKI therapies was recorded and described. Among the two imatinib-resistant CML patients, the first patient was switched to dasatinib and subsequently to ponatinib; the patient currently maintains a complete cytogenetic response (CCyR). The second patient, who has not undergone hematopoietic stem cell transplantation (no suitable matched related donor was available and haploidentical transplantation was not approved at consultation), is currently being treated with nilotinib and has achieved a major molecular response (MMR). The cis/trans configuration of the detected mutations was not determined.Conclusion: Managing TKI-resistant CML remains a challenge. The selection of subsequent TKI therapy must be tailored based on mutational analysis results, clinical history, patient status, and specific therapeutic goals.

Authors

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0304
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY KHÁNG TKI: CA LÂM SÀNG THỰC TIỄN TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC THÀNH PHỐ HỒ CHÍ MINH VÀ Y VĂN

Thị Minh Nhật Dương, Vũ Hà Thanh Lê, Thị Hương Giang Nguyễn
Journal of Clinical Medicine Bach Mai Hospital
Chronic Myeloid Leukemia Treatments
article

ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY KHÁNG TKI: CA LÂM SÀNG THỰC TIỄN TẠI BỆNH VIỆN TRUYỀN MÁU HUYẾT HỌC THÀNH PHỐ HỒ CHÍ MINH VÀ Y VĂN

Thị Minh Nhật Dương, Vũ Hà Thanh Lê, Thị Hương Giang Nguyễn
article en

Abstract

Background: We describe the characteristics, management, and clinical outcomes of patients with chronic myeloid leukemia (CML) who exhibit resistance to tyrosine kinase inhibitors (TKIs).Case presentation: We report two cases of imatinib-resistant CML, detailing their management and follow-up to the present. Information regarding diagnosis, clinical features, treatment history, and assessments before and after switching TKI therapies was recorded and described. Among the two imatinib-resistant CML patients, the first patient was switched to dasatinib and subsequently to ponatinib; the patient currently maintains a complete cytogenetic response (CCyR). The second patient, who has not undergone hematopoietic stem cell transplantation (no suitable matched related donor was available and haploidentical transplantation was not approved at consultation), is currently being treated with nilotinib and has achieved a major molecular response (MMR). The cis/trans configuration of the detected mutations was not determined.Conclusion: Managing TKI-resistant CML remains a challenge. The selection of subsequent TKI therapy must be tailored based on mutational analysis results, clinical history, patient status, and specific therapeutic goals.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon